Lesson plan
ExPEC4V
ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in phase 2 clinical trials. There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054). In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
Article summary
ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in phase 2 clinical trials. There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054). In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.